Frank Rondel
President Donald Trump revealed a detailed health care initiative on Thursday focused on lowering prescription drug costs, reducing health insurance premiums, and enhancing pricing transparency, the customreceipt.com reports, citing sport-tour.pl. The proposal emphasizes direct payments to consumers rather than insurance companies, continuing Trump’s recent advocacy amid debates over the possible extension of the Affordable Care Act’s premium subsidies, which expired at the end of last year.
The plan includes several measures that Trump and Congress have previously promoted, while also building on policies the president implemented during his first term. Among these is a call for lawmakers to codify his “Most Favored Nation” agreements, which negotiate drug prices with more than a dozen pharmaceutical companies. The approach is intended to hold major insurers accountable and provide Americans with more transparent access to health care costs.
Administration officials explained that the plan seeks to address what they describe as inflated pricing practices in both insurance markets and pharmaceutical sales. By sending funds directly to consumers, the administration hopes to empower patients to make informed decisions and incentivize competition among insurers.
Trump also stressed that his plan would increase transparency across the health care system, requiring insurers and pharmaceutical companies to publicly report price data. Officials argue that these measures would discourage arbitrary price hikes and enable consumers to better understand the costs associated with their care.
The president’s initiative comes as lawmakers continue to debate the future of federal health subsidies and broader health care reforms. Trump’s team is urging Congress to act swiftly to approve the proposed measures, framing them as necessary to ease financial burdens for millions of Americans struggling with medical expenses.
The plan further includes provisions aimed at simplifying coverage options, encouraging competition among insurers, and ensuring accountability in negotiations with drug manufacturers. Administration representatives stated that implementing these measures would improve affordability and access while promoting a more transparent health care marketplace.
Earlier we wrote that US Flu Activity Remains High in Week 53 With 17 Pediatric Deaths Reported, CDC Updates